148356-13-2Relevant academic research and scientific papers
SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS
-
Page/Page column 49, (2012/03/27)
The invention provides for novel compounds which are inhibitors of lysine- specific demethylase 1 (LSDl). Such compounds may be used to treat disorders, including cancer.
N3-Arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases
Saavedra, Oscar,Claridge, Stephen,Zhan, Lijie,Raeppel, Franck,Granger, Marie-Claude,Raeppel, Stéphane,Mannion, Michael,Gaudette, Frédéric,Zhou, Nancy,Isakovic, Ljubomir,Bernstein, Naomy,Déziel, Robert,Nguyen, Hannah,Beaulieu, Normand,Beaulieu, Carole,Dupont, Isabelle,Wang, James,Macleod, A. Robert,Besterman, Jeffrey M.,Vaisburg, Arkadii
scheme or table, p. 6836 - 6839 (2010/06/19)
A family of thieno[3,2-b]pyridine based small molecule inhibitors of c-Met and VEGFR2 were designed based on lead structure 2. These compounds were shown to have IC50 values in the low nanomolar range in vitro and were efficacious in human tumo
Inhibitors of VEGF receptor and HGF receptor signaling
-
Page/Page column 69-70, (2010/11/25)
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
